Abstract
Introduction: EBV-associated Gastric Cancer (EBVaGC) comprises about 9% of all cases of GC and constitutes a distinct clinicopathological and molecular entity. The pattern of viral expression in EBVaGC cannot be set to any of the previously EBV-associated malignancies. Several lines of evidence support that viral expression in EBVaGC is characterized by high transcription of the BamH1- A rightward transcript (BART), low-levels of EBNA-1 and lack of LMP1. The high transcription activity of the BamH1-A region is importantly directed to express BART miRNAs, supporting a critical role for these miRNAs during epithelial cell infection and carcinogenesis. Several studies have shown that promoter hypermethylation is also a prominent feature of EBVaGC. Based on the recent TCGA report, the specific fingerprint of genomic alterations in EBVaGC is marked by mutations in PIK3CA, ARID1A and BCOR genes, and amplification of 9p24.1 that harbors the genes for the JAK2, PD-L1 and PD-L2 proteins. The specific programs of viral gene expression, promoter methylation and genomic mutations found in EBVaGC target cell signaling pathways leading to increased proliferation, increased cell survival, immune evasion, augmented EMT and acquisition of stemness features. Less understood is the participation of EBV in chronic gastric inflammation, but some studies argue that EBV, similar to and together with Helicobacter pylori, is an early participant in the GC oncogenic process through promoting chronic inflammation and increased tissue damage.
Conclusion: Here, we discuss the principal and distinctive carcinogenic routes promoted by EBV in the gastric epithelium.Keywords: Gastric cancer, Epstein-Barr virus, BART miRNAs, EBERs, EBNA1, LMP2A, methylator phenotype, chronic inflammation.
Current Cancer Drug Targets
Title:Epstein-Barr Virus-associated Gastric Cancer and Potential Mechanisms of Oncogenesis
Volume: 17 Issue: 6
Author(s): Abigail Morales-Sanchez and Ezequiel M. Fuentes-Panana*
Affiliation:
- Virology and Cancer Research Unit, Children's Hospital of Mexico Federico Gomez, Mexico City, 06720,Mexico
Keywords: Gastric cancer, Epstein-Barr virus, BART miRNAs, EBERs, EBNA1, LMP2A, methylator phenotype, chronic inflammation.
Abstract: Introduction: EBV-associated Gastric Cancer (EBVaGC) comprises about 9% of all cases of GC and constitutes a distinct clinicopathological and molecular entity. The pattern of viral expression in EBVaGC cannot be set to any of the previously EBV-associated malignancies. Several lines of evidence support that viral expression in EBVaGC is characterized by high transcription of the BamH1- A rightward transcript (BART), low-levels of EBNA-1 and lack of LMP1. The high transcription activity of the BamH1-A region is importantly directed to express BART miRNAs, supporting a critical role for these miRNAs during epithelial cell infection and carcinogenesis. Several studies have shown that promoter hypermethylation is also a prominent feature of EBVaGC. Based on the recent TCGA report, the specific fingerprint of genomic alterations in EBVaGC is marked by mutations in PIK3CA, ARID1A and BCOR genes, and amplification of 9p24.1 that harbors the genes for the JAK2, PD-L1 and PD-L2 proteins. The specific programs of viral gene expression, promoter methylation and genomic mutations found in EBVaGC target cell signaling pathways leading to increased proliferation, increased cell survival, immune evasion, augmented EMT and acquisition of stemness features. Less understood is the participation of EBV in chronic gastric inflammation, but some studies argue that EBV, similar to and together with Helicobacter pylori, is an early participant in the GC oncogenic process through promoting chronic inflammation and increased tissue damage.
Conclusion: Here, we discuss the principal and distinctive carcinogenic routes promoted by EBV in the gastric epithelium.Export Options
About this article
Cite this article as:
Morales-Sanchez Abigail and Fuentes-Panana M. Ezequiel*, Epstein-Barr Virus-associated Gastric Cancer and Potential Mechanisms of Oncogenesis, Current Cancer Drug Targets 2017; 17 (6) . https://dx.doi.org/10.2174/1568009616666160926124923
DOI https://dx.doi.org/10.2174/1568009616666160926124923 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Formulation and Application of Biodegradable Nanoparticles Based Biopharmaceutical Delivery - An Efficient Delivery System
Current Pharmaceutical Design Epigenetics: Relations to Disease and Laboratory Findings
Current Medicinal Chemistry Epi-Drugs and Epi-miRs: Moving Beyond Current Cancer Therapies
Current Cancer Drug Targets Quinone-Based Drugs: An Important Class of Molecules in Medicinal Chemistry
Medicinal Chemistry Patent Selections
Recent Patents on DNA & Gene Sequences The Urokinase Receptor as a Potential Target in Cancer Therapy
Current Pharmaceutical Design Strategies to Develop Allergy Immunotherapeutics with Applications of Directed Molecular Evolution
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Editorial (Thematic Issue: Metabolic Disorders, Drug Development, Drug Design and Biomarkers)
Current Pharmaceutical Design Herbal Remedies for the Treatment of Periodontal Disease - A Patent Review
Recent Patents on Drug Delivery & Formulation Glucose Oncometabolism of Esophageal Cancer
Anti-Cancer Agents in Medicinal Chemistry 3-Substituted Isocoumarins as Thymidine Phosphorylase Inhibitors
Letters in Drug Design & Discovery Recent Patents Reveal Microtubules as Persistent Promising Target for Novel Drug Development for Cancers
Recent Patents on Anti-Infective Drug Discovery Antimicrobial Effect of Garlic (Allium sativum)
Recent Patents on Anti-Infective Drug Discovery Mechanisms Underlying Chemotherapy-Induced Neurotoxicity and the Potential for Neuroprotective Strategies
Current Medicinal Chemistry FoxQ1 is a Novel Molecular Target for Pancreatic Cancer and is Associated with Poor Prognosis
Current Molecular Medicine The Interaction of Histone Deacetylase Inhibitors and DNA Methyltransferase Inhibitors in the Treatment of Human Cancer Cells
Current Medicinal Chemistry - Anti-Cancer Agents The Role and Mechanism of Thiol-Dependent Antioxidant System in Bacterial Drug Susceptibility and Resistance
Current Medicinal Chemistry Recent Progress in Pharmacological Research of Antioxidants in Pathological Conditions: Cardiovascular Health
Recent Patents on Anti-Infective Drug Discovery Ion-Pair Reversed-Phase Denaturing HPLC-Based Biotechnology as a Tool for Genetic Analysis
Current Pharmaceutical Analysis Targeting Protein Kinase Inhibitors with Traditional Chinese Medicine
Current Drug Targets